生物靶向治疗高血压的研究进展  

Progress of bio-targeted treatment for hypertension

作　　者：秦萍 廖玉华[1] 邱志华[1] QIN Ping;LIAO Yuhua;QIU Zhihua(Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院心内科,武汉430022

出　　处：《临床心血管病杂志》2023年第1期6-10,共5页Journal of Clinical Cardiology

基　　金：国家自然科学基金面上项目(No:82070522、81974055)。

摘　　要：针对高血压这一主要心血管病危险因素进行有效防治,可以降低心血管病死亡风险。然而,中国高血压的知晓率、治疗率和控制率均处于较低水平,尤其是控制率极低,心血管病防治面临巨大挑战和困境。为进一步探索高血压安全有效的治疗方法,改善治疗依从性,本团队在高血压治疗性疫苗领域多年耕耘,使本研究团队对这一治疗手段的应用前景充满希望。本文将重点介绍高血压生物靶向治疗领域尤其是治疗性疫苗的研究进展,希望以此推动生物靶向治疗高血压领域的基础研究与临床转化。Effective prevention and treatment of hypertension reduce the risk of cardiovascular death.However, the rate of awareness, treatment, and control for hypertension in China is still low, prevention and treatment of cardiovascular diseases is facing huge challenges and difficulties.In order to further explore safe and effective therapeutic methods for hypertension and improve treatment compliance, our team has worked hard for long years in the field of therapeutic hypertension vaccine, which makes us full of hope for the application prospects of therapeutic vaccine.This article will systematically introduce the research progress in the field of bio-targeted treatment for hypertension, especially therapeutic hypertension vaccine, aiming to promote basic research and clinical translation in the field.

关 键 词：高血压 生物靶向治疗 治疗性疫苗 基因靶向治疗 

分 类 号：R544.1[医药卫生—心血管疾病]